Indonesia Pharma Market Entry: BPOM Drug Registration Guide

Indonesia is Southeast Asia’s largest pharmaceutical market, with a population exceeding 270 million. Sustained government investment in universal health coverage and a growing middle class have made it a compelling target for international manufacturers. Yet for all its commercial appeal, Indonesia ranks among the more challenging regulatory environments in the region. The Badan Pengawas Obat dan Makanan, Indonesia’s National Agency of Drug and Food Control, universally known as BPOM, operates a drug registration system that is methodical, documentation-intensive, and unforgiving of submissions that do not meet its specific requirements.

Manufacturers who approach BPOM with assumptions borrowed from FDA or EMA experience will find that Indonesia has its own procedural logic, language requirements, and interpretive expectations. This guide decodes the process step by step.

BPOM's Legal Framework

BPOM’s authority derives from Government Regulation No. 5 of 2021 on Risk-Based Business Licensing, operationalised through BPOM Regulation No. 24 of 2017 (as amended) and BPOM Head Regulation No. 9 of 2024.

All drugs for commercial sale in Indonesia must hold a BPOM Marketing Authorisation, the Nomor Izin Edar (NIE). No product may be imported, distributed, or sold without a valid NIE, issued exclusively in the name of an Indonesian legal entity. Every foreign manufacturer must establish or partner with a local registration holder before the process begins.

Step 1 – Establish a Local Registration Holder

Indonesia requires the NIE to be held by an Indonesian legal entity with a valid BPOM-issued pharmaceutical import licence. Foreign manufacturers cannot hold the NIE in their own name. The local registration holder bears legal accountability for product quality, safety, and regulatory compliance from NIE issuance onward.

Selecting a partner with dedicated regulatory affairs capability, not simply distribution reach, is a strategic decision with long-term compliance consequences. The local partner must manage pharmacovigilance reporting, variation applications, and NIE renewal. Distributors without regulatory competence routinely fail these obligations.

Step 2 – Determine the Registration Category

New drugs (Obat Baru) cover innovative medicines, new chemical entities, new fixed-dose combinations, and biological medicines. These require a complete dossier in ACTD format with full quality, nonclinical, and clinical data.

Generic drugs (Obat Generik) require bioequivalence data against a reference product approved in Indonesia or a recognised reference country, with BE studies conducted at BPOM-accredited sites.

Reference country-based registration is available for products approved in BPOM’s designated reference countries — the US, EU member states, Japan, Australia, Canada, and the UK. This pathway allows a modified dossier relying on the reference country’s assessment, with Indonesian-specific documentation layered on top. It does not eliminate local administrative, labelling, or GMP requirements.

Step 3 – Prepare the ACTD Dossier

The ACTD format closely mirrors CTD in module organisation. Part I covers administrative and product information; Part II covers quality; Part III covers nonclinical; Part IV covers clinical. For manufacturers familiar with CTD submissions, the structure is recognisable, but Indonesian-specific content requirements create substantive differences.

Part I is the most locally demanding. It must include:

Indonesian-language prescribing information (Ringkasan Karakteristik Produk, or RKP): Not a translation of the originator label, it must be drafted to BPOM’s prescribed content structure using approved Indonesian pharmaceutical terminology.
Indonesian labelling: All label text, primary packaging, secondary packaging, and package insert must be in Bahasa Indonesia, conforming to BPOM’s labelling regulation. Directly translating an FDA or EMA label produces a document that fails BPOM’s structural requirements.
Certificate of Pharmaceutical Product (CPP): Issued by the manufacturer’s national health authority, in BPOM-recognised format, and apostilled. BPOM has rejected CPPs for format deviations, apostille irregularities, and insufficient manufacturing site scope detail.
GMP certificates: For each manufacturing site, drug substance, drug product, and any secondary sites, valid GMP certificates from the relevant national authority. BPOM recognises GMP certificates from reference countries and WHO-prequalified manufacturers.
Letter of Authorization: A notarised and apostilled document from the foreign manufacturer authorising the Indonesian registration holder to market the product.

Part II carries a technically significant Indonesia-specific requirement: stability data under Zone IVb conditions (40°C/75% RH). Indonesia’s tropical climate places it firmly in Zone IVb, and BPOM expects stability data generated under these conditions. Manufacturers whose global programmes used Zone IVa (30°C/65% RH) or Zone III conditions, standard for EU and North American markets, must conduct Zone IVb bridging studies. This is one of the most frequently underestimated technical requirements in BPOM submissions.

For country-based registrations, a bridging strategy using the reference country’s assessment report and relevant clinical summaries is acceptable in lieu of a full clinical dossier, subject to BPOM’s review.

Step 4 – Submit Through the e-Registration System

BPOM requires all applications to be submitted through its electronic portal (e-Reg), accessed through the Indonesian registration holder’s BPOM account. Documents must be uploaded as PDFs in the ACTD structure, following BPOM’s file naming conventions precisely. Submissions that do not conform are rejected at screening without substantive review. BPOM conducts a 10-working-day screening review to confirm administrative completeness. Common screening failures include improperly formatted CPPs, incomplete GMP documentation, and missing signed declarations.

Step 5 – Navigate the Review Process

Following acceptance, substantive review is conducted by BPOM’s evaluation directorate. Published target timelines are: new drugs, 300 working days; generic drugs, 100 working days; reference country-based new drug registration, 150 working days from acceptance.

These clocks pause during additional data request periods (Surat Permintaan Tambahan Data), with a 60-working-day response window per request. Multiple request rounds are common for new drugs, and each adds material elapsed time. Total elapsed time for new drug registrations commonly reaches 24 to 36 months. The most frequent triggers are incomplete Indonesian labelling, GMP certificate deficiencies, CPP apostille issues, and Zone IVb stability data gaps.

Step 6 – Post-NIE Obligations

NIE issuance creates a defined set of ongoing compliance obligations.

Pharmacovigilance: Serious adverse drug reactions must be reported to BPOM within 15 calendar days. Periodic Safety Update Reports must be submitted in accordance with BPOM’s requirements, aligned with the product’s International Birth Date.

Post-market study commitments: For new drugs, BPOM typically attaches Phase IV safety study requirements to the NIE, with defined timelines for commencement and report submission.

Variations: Changes to manufacturing, formulation, labelling, or indications require BPOM variation applications before implementation. Major and minor variation categories carry different documentation requirements and timelines.

NIE renewal: Drug registrations are valid for five years. A lapsed NIE requires a new registration process, renewal is not automatic and cannot be submitted after expiry.

Conclusion

BPOM drug registration demands Indonesia-specific preparation at every stage. The reference country pathway reduces the clinical evidence burden for already-approved products, but leaves the administrative, labelling, GMP documentation, and stability data requirements fully intact. Manufacturers who invest in accurate Indonesian-language labelling and RKP, Zone IVb stability data, capable local registration partners, and thoroughly prepared ACTD dossiers achieve faster, cleaner reviews than those who adapt global submissions without adequate local depth.

How can DDReg help?

DDReg supports pharmaceutical manufacturers entering the Indonesian market with end-to-end regulatory services for BPOM registration, including ACTD dossier preparation, Indonesian-language RKP and labelling development, CPP and GMP documentation management, e-Reg submission, and post-NIE pharmacovigilance programme setup across new drug, generic, and biosimilar categories.